Moleculin Biotech is a late-stage pharmaceutical development company evaluating Annamycin, a next-generation anthracycline designed to overcome cardiotoxicity and resistance limitations of existing chemotherapy drugs, primarily for relapsed/refractory acute myeloid leukemia and soft tissue sarcoma. The company operates three technology portfolios derived from University of Texas MD Anderson Cancer Center discoveries: the Annamycin portfolio as its lead program in clinical trials, the WP1066 immune modulators for glioblastoma and brain tumors, and WP1122 glycolysis inhibitors also for glioblastoma. As a development-stage company with no product revenues, Moleculin relies on sponsored research funding from MD Anderson, investigator-initiated trials funded by external collaborators, royalties from a sublicense agreement for non-human applications, and plans to pursue future commercialization through partnerships with larger pharmaceutical companies or contracted sales capabilities upon regulatory approval.